BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grebely J, Hajarizadeh B, Lazarus JV, Bruneau J, Treloar C; International Network on Hepatitis in Substance Users. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. Int J Drug Policy 2019;72:1-10. [PMID: 31345644 DOI: 10.1016/j.drugpo.2019.07.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Valencia J, Lazarus JV, Ceballos FC, Troya J, Cuevas G, Resino S, Torres-Macho J, Ryan P. Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-care. Liver Int 2021. [PMID: 34767680 DOI: 10.1111/liv.15095] [Reference Citation Analysis]
2 Coupland H, Day C, Haber P, Pritchard-Jones J, McKee K, George J, McCaughan G. Client resistance to hepatitis C treatment initiation in opioid agonist treatment clinics in Sydney, Australia: A qualitative study. Drug Alcohol Rev 2021. [PMID: 34839561 DOI: 10.1111/dar.13414] [Reference Citation Analysis]
3 Giuliani R, Casigliani V, Fornili M, Sebastiani T, Freo E, Arzilli G, Scardina G, Baglietto L, Tavoschi L, Ranieri R. HCV micro-elimination in two prisons in Milan, Italy: A model of care. J Viral Hepat 2020;27:1444-54. [PMID: 32815623 DOI: 10.1111/jvh.13376] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
4 Bouare N, Keita M, Delwaide J. Comment on review article: Chronic hepatitis C virus infection cascade of care in pediatric patients. World J Gastroenterol 2022; 28(14): 1494-1498 [DOI: 10.3748/wjg.v28.i14.1494] [Reference Citation Analysis]
5 Liu Y, Zhang H, Zhang L, Zou X, Ling L. Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China. Int J Environ Res Public Health 2020;17:E800. [PMID: 32012839 DOI: 10.3390/ijerph17030800] [Reference Citation Analysis]
6 Ifeachor AP, Houck KK, Schulte S, Ansara E, Johnson AJ, Carr TA, Liangpunsakul S. HCV eradication in veterans with underlying mental health disorders and substance use. J Am Pharm Assoc (2003) 2020;60:1037-1043.e3. [PMID: 32948462 DOI: 10.1016/j.japh.2020.08.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Reygosa C, Morales-Arraez D, Hernández-Bustabad A, Melián Baute L, Hernández-Guerra M. Hepatitis C-treated patients as a potential source for referral of new cases. Gastroenterol Hepatol 2021:S0210-5705(21)00148-5. [PMID: 34023471 DOI: 10.1016/j.gastrohep.2021.03.006] [Reference Citation Analysis]
8 Akiyama MJ, Muller A, Huang O, Lizcano J, Nyakowa M, Riback L, Ross J, Bundi H, Kulabi ES, Mwangi AM, Musyoki H, Cherutich P, Kurth A. Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: A qualitative study. Glob Public Health 2021;:1-13. [PMID: 33689563 DOI: 10.1080/17441692.2021.1896763] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Seaman A, King CA, Kaser T, Geduldig A, Ronan W, Cook R, Chan B, Levander XA, Priest KC, Korthuis PT. A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment. Int J Drug Policy 2021;:103359. [PMID: 34325969 DOI: 10.1016/j.drugpo.2021.103359] [Reference Citation Analysis]
10 Grebely J, Collins AB, Artenie AA, Sutherland R, Meyer JP, Barocas JA, Falade-Nwulia O, Cepeda JA, Cunningham EB, Hajarizadeh B, Lafferty L, Lazarus JV, Bonn M, Marshall AD, Treloar C. Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. Int J Drug Policy 2021;96:103469. [PMID: 34610884 DOI: 10.1016/j.drugpo.2021.103469] [Reference Citation Analysis]
11 Gutiérrez García ML, Gómez Perosanz R, Acedo Sanz JM, Delgado-Iribarren García-Campero A, Claudio Domínguez I, Domenech Gómez-Imaz A, Pérez Encinas M, de la Fuente Hermosín I, Fabero Jimenez A, Fernández Rodríguez CM. Coordinated assistance plan for the elimination of hepatitis C virus at the centro de ayuda integral al drogodependiente (CAID (Comprehensive Care Centre for Drug Addicts)). Gastroenterol Hepatol 2021;44:214-20. [PMID: 33162188 DOI: 10.1016/j.gastrohep.2020.08.002] [Reference Citation Analysis]
12 Fiore V, De Matteis G, Ranieri R, Saderi L, Pontali E, Muredda A, Ialungo AM, Caruso R, Madeddu G, Sotgiu G, Babudieri S. HCV testing and treatment initiation in an Italian prison setting: A step-by-step model to micro-eliminate hepatitis C. Int J Drug Policy. 2021;90:103055. [PMID: 33310637 DOI: 10.1016/j.drugpo.2020.103055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
13 Sherbuk JE, Tabackman A, McManus KA, Kemp Knick T, Schexnayder J, Flickinger TE, Dillingham R. A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South. Harm Reduct J 2020;17:64. [PMID: 32948189 DOI: 10.1186/s12954-020-00409-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Austin EJ, Tsui JI, Barry MP, Tung E, Glick SN, Ninburg M, Williams EC. Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma. J Subst Abuse Treat 2021;:108684. [PMID: 34911656 DOI: 10.1016/j.jsat.2021.108684] [Reference Citation Analysis]
15 Muller A, Vlahov D, Akiyama MJ, Kurth A. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis. Int J Environ Res Public Health 2020;17:E4951. [PMID: 32659974 DOI: 10.3390/ijerph17144951] [Reference Citation Analysis]
16 Bouare N, Keita M, Delwaide J. Comment on review article: Chronic hepatitis C virus infection cascade of care in pediatric patients. WJG 2022;28:1494-8. [DOI: 10.3748/wjg.v28.i14.1494] [Reference Citation Analysis]
17 Morales-Arraez D, Hernández-Bustabad A, Medina-Alonso MJ, Santiago-Gutiérrez LG, García-Gil S, Diaz-Flores F, Pérez-Pérez V, Nazco J, Fernandez de Rota Martin P, Gutiérrez F, Hernández-Guerra M. Telemedicine and decentralized hepatitis C treatment as a strategy to enhance retention in care among people attending drug treatment centres. Int J Drug Policy 2021;94:103235. [PMID: 33838399 DOI: 10.1016/j.drugpo.2021.103235] [Reference Citation Analysis]
18 Midgard H, Ulstein K, Backe Ø, Foshaug T, Sørli H, Vennesland K, Nilssen D, Dahl EH, Finbråten AK, Wüsthoff L, Dalgard O. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway. Int J Drug Policy 2021;:103165. [PMID: 33642182 DOI: 10.1016/j.drugpo.2021.103165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Von den Hoff DW, Berden FAC, Atsma F, Schellekens AFA, Drenth JPH. Against All Odds? Addiction History Associated with Better Viral Hepatitis Care: A Dutch Nationwide Claims Data Study. J Clin Med 2022;11:1146. [PMID: 35207419 DOI: 10.3390/jcm11041146] [Reference Citation Analysis]
20 Midgard H, Finbråten AK, Malme KB, Berg-Pedersen RM, Tanum L, Olsen IC, Bjørnestad R, Dalgard O. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs. Trials 2020;21:524. [PMID: 32539853 DOI: 10.1186/s13063-020-04434-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Chen Y, Wu L, Li P, Hao X, Yang X, Xi G, Liu W, Feng Y, He H, Shi C. Polysaccharide Based Hemostatic Strategy for Ultrarapid Hemostasis. Macromol Biosci 2020;20:1900370. [DOI: 10.1002/mabi.201900370] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
22 Folch C, Saludes V, Reyes-Ureña J, Antuori A, Ibáñez N, Majó X, Colom J, Matas L, Casabona J, Martró E; HepCdetect II Study Group. The hepatitis C care cascade among people who inject drugs accessing harm reduction services in Catalonia: Major gaps for migrants. Int J Drug Policy 2021;90:103057. [PMID: 33310634 DOI: 10.1016/j.drugpo.2020.103057] [Reference Citation Analysis]